Pfizer (PFE) : Destrier Capital Management added new position in Pfizer during the most recent quarter end. The investment management firm now holds 310,000 shares of Pfizer which is valued at $10.3 Million , the company said in a statement filed on May 13, 2016 with the SEC.Pfizer makes up approximately 7.24% of Destrier Capital Management’s portfolio.
Other Hedge Funds, Including , I.g. Investment Management Ltd. boosted its stake in PFE in the latest quarter, The investment management firm added 1,887,291 additional shares and now holds a total of 10,097,757 shares of Pfizer which is valued at $335.1 Million. Pfizer makes up approx 1.34% of I.g. Investment Management Ltd.’s portfolio.Bank Of Nova Scotia Trust Co reduced its stake in PFE by selling 44,605 shares or 20.86% in the most recent quarter. The Hedge Fund company now holds 169,217 shares of PFE which is valued at $5.6 Million. Pfizer makes up approx 0.76% of Bank Of Nova Scotia Trust Co’s portfolio.Burney Co boosted its stake in PFE in the latest quarter, The investment management firm added 1,086 additional shares and now holds a total of 37,919 shares of Pfizer which is valued at $1.3 Million. Pfizer makes up approx 0.09% of Burney Co’s portfolio.
Pfizer opened for trading at $34.12 and hit $34.4 on the upside on Wednesday, eventually ending the session at $34.35, with a gain of 0.73% or 0.25 points. The heightened volatility saw the trading volume jump to 2,10,36,679 shares. Company has a market cap of $208,328 M.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Many Wall Street Analysts have commented on Pfizer. Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.